Company Overview and News

 
KKB Engineering to bid for Sarawak water jobs

9h thestar.com.my
KUCHING: KKB Engineering Bhd will bid for several projects under Sarawak’s ambitious billion-ringgit state water grid development programme as it kicks off.
9466

 
Petronas expected to produce oil from D28 offshore Bintulu field next month

2018-10-10 thestar.com.my
KUCHING: Petroliam Nasional Bhd (Petronas) is expected to produce oil next month from the D28 offshore oil field, which is about 85 km north-west of Bintulu.
9466

 
OM Sarawak ramps up output with operation of 16th furnace

2018-08-27 thestar.com.my
OMH has a 75% stake in OM Materials Sarawak. Cahya Mata Sarawak Bhd (CMS) owns the remaining 25% equity interest in the joint venture company
2852 CISEY CNSD SSUMF CISXF 9466

 
Cahya Mata Sarawak records strong 2Q net profit owing to improved results of its associates

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): Sarawak State infrastructure facilitator Cahya Mata Sarawak Bhd (CMSB) saw its net profit for the second quarter ended June 30, 2018 (2QFY18) leap by 59.5% to RM91.63 million from RM57.43 million mainly attributed to the increase in share of results of its associates.
2852 BSMAF 9466 1818

 
Improved revenue seen for KKB

2018-08-09 theedgemarkets
KKB Engineering Bhd (Aug 8, 91.5 sen) Maintain buy with a target price (TP) of RM1.13: KKB Engineering Bhd’s 61.8% subsidiary OceanMight Sdn Bhd (OMSB) has secured a combined contract of RM226 million from Petronas Carigali Sdn Bhd for the provision of engineering, procurement, construction and commissioning of Wellhead Platforms for the D18 Phase Two project.
9466

 
Dufu, Frontken, Tien Wah, Hartalega, Uzma, Inta Bina, Advancecon, Three-A, KKB Engineering, Versatile Creative and MISC

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Dufu Technology Corp Bhd, Frontken Corp Bhd, Tien Wah Press Holdings Bhd, Hartalega Holdings Bhd, Uzma Bhd, Inta Bina Group Bhd, Metronic Global Bhd, Advancecon Holdings Bhd, Three-A Resources Bhd, KKB Engineering Bhd, Versatile Creative Bhd and MISC Bhd.
0012 4995 5347 TNABY TNABF 5168 7374 9466 0043 7233 HRGHY

 
KKB Engineering chalks up fourth straight quarterly profit in 2Q

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): KKB Engineering Bhd posted its fourth straight quarter of profit in the second financial quarter ended June 30, 2018 (2QFY18), with a net profit of RM1.76 million compared with a net loss of RM7.2 million a year ago.
BSMAF 9466 1818

 
EPCC job from Petronas Carigali valued at RM226m — KKB

2018-08-07 theedgemarkets
KUALA LUMPUR: KKB Engineering Bhd said it commenced engineering, procurement, construction and commissioning works on the D18 JT-D well head platform off Malaysia last month, which together with the D28 Phase 1 project have a total contract value of RM226 million.
BSMAF 9466 1818

 
Trading ideas: PRG, KKB, Axis REIT, Only World, IJM Plantations

2018-08-07 thestar.com.my
KUALA LUMPUR: JF Apex Research expects PRG Holdings Bhd , KKB Engineering Bhd , Axis Real Estate Investment Trust (Axis REIT), Only World Group Holdings Bhd and IJM Plantations Bhd to generate trading interest following their latest news.
5106 5260 2216 7168 9466

 
KKB up 3.98% on starting EPCC works for Petronas Carigali job

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): KKB Engineering Bhd rose 3.98% this morning after the company said it has commenced engineering, procurement, construction and commissioning (EPCC) works for the D18 JT-D wellhead platform off Malaysia last month, which together with the D28 Phase 1 project have a total contract value of RM226 million.
9466

 
KLCI seen trending sideways, immediate support at 1,764

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI is seen trending sideways today with immediate support at 1,764, despite the firmer overnight close at most global markets, as buying support at the local bourse is likely to be lukewarm.
0177 5106 5260 7168 1481 9466

 
SD Plantation, PRG, Pasukhas, KKB, SKH, Axis REIT, OWG, MCT and Advance Synergy

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): Based on corporate announcements and news flow today, stocks in focus for Tuesday (Aug 7) may include the following: Sime Darby Plantation Bhd, PRG Holdings Bhd, Pasukhas Group Bhd, KKB Engineering Bhd, SKH Consortium Bhd, Axis Real Estate Investment Trust, Only World Group Holdings Bhd, MCT Bhd and Advance Synergy Bhd.
0177 5106 5260 7168 BSMAF 1481 9466 1818

 
KKB Engineering up 3.5% on EPCC job from Petronas Carigali

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): KKB Engineering Bhd reversed a decline of 0.59% seen in early trade to rise 3.5% to 87.5 sen at 3.39pm today, following the announcement of the engineering, procurement, construction and commissioning (EPCC) works for D18 JT-D wellhead platform off Malaysia last month, which together with the D28 Phase 1 project have a total contract value of RM226 million.
9466

 
EPCC job from Petronas Carigali valued at RM226m — KKB Engineering

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): KKB Engineering Bhd said it has commenced engineering, procurement, construction and commissioning (EPCC) works for the D18 JT-D wellhead platform off Malaysia last month, which together with the D28 Phase 1 project have a total contract value of RM226 million.
BSMAF 9466 1818

58
Consolidation of the oil and gas sector not fast enough

2018-06-12 thestar.com.my
The steady recovery in crude oil prices over the past one year has yet to have a big positive impact on OGSE players. This is partly because oil majors have yet to increase their capex in a big way.
RDS.B RDS.A XOM RDSB RDSA 8133 5255 9466 BHI 7206 5703 RYDBF RYDAF BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...